StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)

Close on Nov 18, 2026Market cap $6.09BP/E –Yield –

Arrowhead Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Arrowhead Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $669.50M, up 16.8% year over year. For fiscal 2025 it was $829.45M, up 23258.2% from the year before. Over ten years it grew 115.6% a year on average. The highest annual figure on record is $829.45M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Sep 30, 2025$829.45M+23258.2%
FY2024Sep 30, 2024$3.55M-98.5%
FY2023Sep 30, 2023$240.74M-1.0%
FY2022Sep 30, 2022$243.23M+75.9%
FY2021Sep 30, 2021$138.29M+57.2%
FY2020Sep 30, 2020$87.99M-47.9%
FY2019Sep 30, 2019$168.80M+945.7%
FY2018Sep 30, 2018$16.14M-48.6%
FY2017Sep 30, 2017$31.41M+19736.5%
FY2016Sep 30, 2016$158.33K-58.6%
FY2015Sep 30, 2015$382.00K+118.3%
FY2014Sep 30, 2014$175.00K-39.7%
FY2013Sep 30, 2013$290.27K+97.6%
FY2012Sep 30, 2012$146.88K-50.4%
FY2011Sep 30, 2011$296.14K–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$75.25M+171.0%
Q2 FY2026CQ1 2026Mar 31, 2026$73.74M-86.4%
Q1 FY2026CQ4 2025Dec 31, 2025$264.03M+10461.3%
Q4 FY2025CQ3 2025Sep 30, 2025$256.47M–
Q3 FY2025CQ2 2025Jun 30, 2025$27.77M–
Q2 FY2025CQ1 2025Mar 31, 2025$542.71M–
Q1 FY2025CQ4 2024Dec 31, 2024$2.50M-29.6%
Q4 FY2024CQ3 2024Sep 30, 2024$0-100.0%
Q3 FY2024CQ2 2024Jun 30, 2024$0-100.0%
Q2 FY2024CQ1 2024Mar 31, 2024$0-100.0%
Q1 FY2024CQ4 2023Dec 31, 2023$3.55M-94.3%
Q4 FY2023CQ3 2023Sep 30, 2023$16.10M-49.0%
Q3 FY2023CQ2 2023Jun 30, 2023$15.83M-51.2%
Q2 FY2023CQ1 2023Mar 31, 2023$146.27M-3.6%
Q1 FY2023CQ4 2022Dec 31, 2022$62.55M+127.9%
Q4 FY2022CQ3 2022Sep 30, 2022$31.58M-17.5%
Q3 FY2022CQ2 2022Jun 30, 2022$32.41M-29.4%
Q2 FY2022CQ1 2022Mar 31, 2022$151.81M+362.7%
Q1 FY2022CQ4 2021Dec 31, 2021$27.44M+28.8%
Q4 FY2021CQ3 2021Sep 30, 2021$38.28M+401.6%
Q3 FY2021CQ2 2021Jun 30, 2021$45.89M+67.6%
Q2 FY2021CQ1 2021Mar 31, 2021$32.81M+39.4%
Q1 FY2021CQ4 2020Dec 31, 2020$21.30M-27.7%
Q4 FY2020CQ3 2020Sep 30, 2020$7.63M-82.4%
Q3 FY2020CQ2 2020Jun 30, 2020$27.38M-35.9%
Q2 FY2020CQ1 2020Mar 31, 2020$23.53M-51.1%
Q1 FY2020CQ4 2019Dec 31, 2019$29.46M-15.0%
Q4 FY2019CQ3 2019Sep 30, 2019$43.29M+284.7%
Q3 FY2019CQ2 2019Jun 30, 2019$42.70M+5770.0%
Q2 FY2019CQ1 2019Mar 31, 2019$48.15M+7306.0%
Q1 FY2019CQ4 2018Dec 31, 2018$34.66M+887.5%
Q4 FY2018CQ3 2018Sep 30, 2018$11.26M+29.2%
Q3 FY2018CQ2 2018Jun 30, 2018$727.38K-92.2%
Q2 FY2018CQ1 2018Mar 31, 2018$650.13K-92.8%
Q1 FY2018CQ4 2017Dec 31, 2017$3.51M-19.6%
Q4 FY2017CQ3 2017Sep 30, 2017$8.71M+27784.1%
Q3 FY2017CQ2 2017Jun 30, 2017$9.34M–
Q2 FY2017CQ1 2017Mar 31, 2017$8.99M–
Q1 FY2017CQ4 2016Dec 31, 2016$4.37M–
Q4 FY2016CQ3 2016Sep 30, 2016$31.25K–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?